Research & Development: Page 72
-
PharmaVoice Team/PharmaVoice
Raise Your Voice: Letters
Pricing: At What Cost In your March 2002 article “The Cost of Doing Business,” I criticized as incorrect the conclusion that high R&D costs cause high pharma prices. A more economically sensible conclusion is that high pharma prices cause companies to undertake higher cost, more diffi cult, a...
By PharmaVoice Team • Aug. 13, 2009 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
PUBLISHER Lisa Banket EDITOR Taren Grom CREATIVE DIRECTOR Marah Walsh DIRECTOR OF SALES Darlene Kwiatkowski CONTRIBUTING EDITORS Diane Hoffman Virginia Kirk Denise Myshko Kim Ribbink Deborah Ruriani Lynda Sears Copyright 2002 by PharmaLinx LLC, Titusville, NJ Printed in the U.S.A. Volume Two, Num...
By Taren Grom • Aug. 13, 2009 -
Explore the Trendline➔
Stock via Getty Images
TrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
The Creative Challenge
BY TAREN GROM CHARLENE PROUNIS Our clients are afraid to take risks. The original concept often gets very watered down and loses its flair.There are so many people who are involved in the decision making process, by the time an ad gets approved it’s defaulted to the lowest common denominator. Cha...
By PharmaVoice Team • Aug. 12, 2009 -
PharmaVoice Team/PharmaVoice
Mark Eisenach — The Mark of a Leader
With more than 75% of all clinical trials failing to meet enrollment deadlines, costing drug makers more than a million dollars a day in potential sales, Mark Eisenach’s mission is to help solve the industry’s chronic problem surrounding patient and investigator recruitment. Mark LEADER of a T...
By Kim Ribbink • Aug. 12, 2009 -
PharmaVoice Team/PharmaVoice
Vanlev: Coming Soon
In a second round for a drug that once was predicted to become a high flier, BristolMyers Squibb is one FDA approval away from launching the next best medication for the treatment of hypertension, a condition that affects about 50 million Americans. Nearly two years ago, BristolMyers Squibb was s...
By PharmaVoice Team • Aug. 12, 2009 -
PharmaVoice Team/PharmaVoice
What's New
Ribotsky Worldwide Inc., a fullservice communications company, has expanded its offerings to clients through a new division. Strategic Healthcare Solutions provides healthcare markettrends analy sis, competitive market and brand analysis, and healthcare marketcommunications analysis. Strate gic H...
By PharmaVoice Team • Aug. 12, 2009 -
PharmaVoice Team/PharmaVoice
PharmaOutlet
In a nod to the founding fathers, several states have started a revolution against the tyranny of high margin pharmaceuticals with the uninsured elderly playing the role of constituents deprived of their rights. This time the battlefield is the U.S. courts, and lawyers representing both sides are...
By Don Sharpe • Aug. 11, 2009 -
PharmaVoice Team/PharmaVoice
What's on your mind: Opinions
The Time Has Come The idea of setting up a separate agency to oversee postmarketing surveillance has been proposed over the past two to three decades — perhaps now its time has come. I would endorse using a new source of user funds to establish a quasiautonomous agency separate from FDA and indus...
By PharmaVoice Team • Aug. 11, 2009 -
PharmaVoice Team/PharmaVoice
Who's on the List by Section
The Commanders & Chiefs 12 Ahsan Awan Ross Bjella Laurie Cooke, R.Ph. John Farinacci Tuan Ha-Ngoc Fred Hassan Thomas Hughes, Ph.D. Greg Johnson Rick Keefer Kyle Kennedy William Maichle John Maraganore, Ph.D. Francois Nader, M.D. Nader Naeymi-Rad Angus Russell Laurent Schockmel, DVM Jeffrey St...
By PharmaVoice Team • July 30, 2009 -
PharmaVoice Team/PharmaVoice
The Reading List
NON-FICTION Memo to the President: How We Can Restore America’s Reputation and Leadership • Madeleine Albright Making it all Work: Winning at the Game of Work and the Business of Life • David Allen Who Goes First?: The Story of Self-Experimentation in Medicine • Lawrence K. Altman It’s Not About ...
By PharmaVoice Team • July 30, 2009 -
PharmaVoice Team/PharmaVoice
E-Media
New Electronic and Web-based Applications, Sites, and Technologies Featured Briefs: GfK Announces Additions to Marketing Research Portfolio TVG Offers New Forecasting Suite QuestaWeb Offerings Reduce Costs for Importers, Exporters Skila Launches Global Market Access Management Solution StudyManag...
By PharmaVoice Team • July 29, 2009 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Sales, Marketing, and R&D Trends from Industry Analysts Featured Briefs: Clarity of Strategy Crucial to Pharma Licensing Success Personalized Medicine and the Payoff for Diagnostic Companies China Remains Promising Market Despite Global Pharma Challenges Sidebar: China Disclosed M&A Deals...
By PharmaVoice Team • July 29, 2009 -
PharmaVoice Team/PharmaVoice
Who's on the List by Company
Acadia Pharmaceuticals Inc. John Kaiser 68 Acorda Therapeutics Inc. Ron Cohen, M.D. 39 Alnylam Pharmaceuticals John Maraganore, Ph.D. 24 AMR Research Hussain Mooraj 107 Amylin Pharmaceuticals Joseph Martinez 76 Astellas Pharma US Charlotte Berlin 64 AVEO Pharmaceuticals Inc. Tuan Ha-Ngoc 20 Avid ...
By PharmaVoice Team • July 29, 2009 -
PharmaVoice Team/PharmaVoice
Contents
12 Commanders & Chiefs These inspirational leaders take charge of their companies’ growth and success by providing a clear vision, developing innovative solutions, and making the tough decisions. 34 The Entrepreneurs Forward-thinking, committed, and dedicated are just the tip of the adjective...
By PharmaVoice Team • July 29, 2009 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
The PharmaVOICE 100: 2009 PharmaVOICE is honored to bring you its fifth annual special issue celebrating 100 of the most inspiring individuals in the life-sciences industry. This issue, which is called the feel-good issue of the year, is packed with in-depth profiles showcasing the industry’s bes...
By Taren Grom • July 29, 2009 -
PharmaVoice Team/PharmaVoice
Patient ADVOCATES
Peg Connelly, Kforce Clinical Research Inc. Paula Garrett, Eli Lilly & Co. Kathy Giusti, Multiple Myeloma Research Foundation and Multiple Myeloma Research Consortiumm Stanley S. Wulf, M.D., F.A.C.O.G., InfoMedics Inc. Emma Sergeant, RGN, RSCN, Fast4wD Ogilvy Lyndi Hirsch, Genentech USA Patie...
By PharmaVoice Team • July 28, 2009 -
PharmaVoice Team/PharmaVoice
The Researchers & SCIENTISTS
Dr. Lee Babiss was the captain of his Ultimate Frisbee team in college. A consummate life-sciences professional, Dr. Lee Babiss, Global Head of Pharma Research at Roche, is an insightful scientist with a love for research and a passion for patients. Dr. Lee Babiss, Roche Dr. Larry Blankstein, Gen...
By PharmaVoice Team • July 28, 2009 -
PharmaVoice Team/PharmaVoice
The CHANGE agents
Vaughn Anthony, D. Anderson & Co. Jeffrey Berkowitz, Schering-Plough Pharmaceuticals Debbie Botwick, Pfizer Oliver Chateau, GlaxoSmithKline Nancy Corkum, Johnson & Johnson Michelle Dipp, GSK initiative Mary Hensley Evans, imc2 Health and Wellness Frederick Foard, Communications Media Inc....
By PharmaVoice Team • July 28, 2009 -
PharmaVoice Team/PharmaVoice
The ENTREPRENEURS
Michael Beckloff, Beckloff Associates Dr. Joan Bradley, The JB Ashtin Group Faruk Capan, Intouch Solutions Gary Beer, DOV Pharmaceutical, Inc. Ron Cohen, Acorda Therapeutics Inc. Elizabeth Apelles, Greater than One Jaswinder Chadha, marketRx Denise Deman-Williams, Bench International Jay Deakins,...
By PharmaVoice Team • July 28, 2009 -
PharmaVoice Team/PharmaVoice
Commanders & CHIEFS
Ahsan Awan, Global CINRG Inc. Ross Bjella, DDN Pharmaceutical Logistics Laurie Cooke, The Healthcare Businesswomen’s Association (HBA) John Farinacci, ResearchPoint Dr. Thomas Hughes, Zafgen Greg Johnson, Strategic Business Research Rick Keefer, Publicis Strategic Solutions Group Tuan Ha Ngoc, AV...
By PharmaVoice Team • July 28, 2009 -
PharmaVoice Team/PharmaVoice
Breaking Down The Complex
While the U.S. Food and Drug Administration has accelerated its review and approval of new medicines, drug developers’ increased focus on complex diseases, such as cancer and neurological disorders, as well as disorders for which there are few effective therapies, has resulted in longer clinical ...
By PharmaVoice Team • June 8, 2009 -
PharmaVoice Team/PharmaVoice
Table of Contents
Letter from the Editor The Forum Breaking Down the Complex: Regardless of the current economic climate and the increasing complexities and costs of drug development, the objective for clinical operations executives remains the same: identify the top people and most advanced technologies, and put ...
By PharmaVoice Team • June 8, 2009 -
PharmaVoice Team/PharmaVoice
Clinical Monitoring: How EDC Has Changed the Game
Clinical Monitoring: How EDC Has Changed the Game As the use of electronic data capture (EDC) systems increasingly becomes mainstream in clinical research, replacing the use of paper CRFs, much focus has been placed on the revolutionary impact this technology has had on the role of clinical da...
By PharmaVoice Team • June 8, 2009 -
PharmaVoice Team/PharmaVoice
Adapting to Meet Today's Needs
From the FDA to the top 20 global biopharmaceutical companies, service providers, and care givers everyone is searching for ways to improve process, procedures, and margins. No one is spared from the impact of our economic situation today and the market is demanding greater focus on quality and s...
By PharmaVoice Team • June 8, 2009 -
PharmaVoice Team/PharmaVoice
Metrics Predict Success for Clinical Trials
A CenterWatch survey says 70% of clinical trials run late, something that has changed little over the years. In response, the clinical trial industry is making better use of metrics that improve feasibility planning and selection of trial sites. Metrics to Improve Trial Feasibility Assessment Al...
By PharmaVoice Team • June 8, 2009
Previous
